July 2025 – Page 13

Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic

2 months ago talkbio0Tagged Actithera, Andreas Goutopoulos, clinic entry, financing characteristics, Radiopharma, Series

Actithera; radiopharma; Series A; biotech funding; clinic entry; Andreas Goutopoulos; startup financing

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

2 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments

RFK Jr. Cancels USPSTF Meeting Amid Healthcare Groups’ Integrity Concerns

2 months ago talkbio0Tagged CHARGE Syndrome, Congress (U.S. Legislature), expert, Health Policy, meeting cancellation, Preventive Care, RFK Jr., USPSTF

RFK Jr.; USPSTF; meeting cancellation; preventive care; health policy; HHS; Congress; expert panel integrity

Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio

2 months ago talkbio0Tagged Acquisition, COPD, Drug Industry, Keytruda patent, Merck, Ohtuvayre, Pharma, Respiration Disorders, Verona

Merck; Verona Pharma; acquisition; Ohtuvayre; COPD; respiratory disease; Keytruda patent; biotech; pharmaceutical industry

FDA Approves Updated Dosing for Lilly’s Kisunla to Lower Brain Swelling Risk

2 months ago talkbio0Tagged Alzheimer 's disease, Cerebral Edema, dosing, eli lilly, Kisunla, label update, Neuregulins, Safety, Treatment Protocols, United States Food and Drug Administration

FDA; Kisunla; Eli Lilly; Alzheimer’s disease; dosing regimen; brain swelling; ARIA; safety; label update; TRAILBLAZER-ALZ 6

Rhythm’s Oral MC4R Agonist Bivamelagon Shows Promising Results in Rare Obesity Type

2 months ago talkbio0Tagged Agonist, Bivamelagon, Body mass index procedure, Clinical Trials, Hypothalamic obesity, MC4R protein, human, oral weight loss drug, Rhythm

Rhythm Pharmaceuticals; oral weight-loss drug; bivamelagon; MC4R agonist; Phase 2 trial; hypothalamic obesity; BMI reduction; clinical trial results

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

2 months ago talkbio0Tagged Blood - brain barrier anatomy, Brain Delivery Module, dealmaking, Eledon, Iambic, Neuroscience discipline, Novartis, Revolution Medicines, Sernova, Sironax

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma

2 months ago talkbio0Tagged AAVS1 gene, Alexion, AstraZeneca, Capsid, gene therapy, genomic medicines, Infrequent, JCR, JUST-AAV, Licensing Deal

AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Drug Discovery, Drug Industry, Iambic Therapeutics, milestone payments, Neoplasms, NeuralPLexer, propane, RAS-addicted cancers, Revolution Medicines

Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments

Novartis Gains World-First Approval of Malaria Treatment for Babies

2 months ago talkbio0Tagged Africa, Approved, artemether-lumefantrine, Coartem, Infant, Infant, Newborn, Malaria, Novartis, Swissmedic, venture

Novartis; malaria; Coartem Baby; Swissmedic; newborns; infants; Africa; approval; artemether-lumefantrine; Medicines for Malaria Venture; not-for-profit